Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.43 |
| ▸ | IGF1R | P08069 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404122 | 0.91 | TNK2 (0.51) | TNK2 | |
| SCHEMBL12648398 | 0.91 | TNK2 (0.45) | TNK2IGF1RKMT2ARAF1SRC | |
| SCHEMBL13629017 | 0.88 | TNK2 (0.47) | TNK2KMT2ARAF1SRCBTK | |
| SCHEMBL8404266 | 0.84 | TNK2 (0.40) | TNK2KMT2APKMTSHRRAF1 | |
| SCHEMBL8404277 | 0.82 | TNK2 (0.41) | TNK2RAF1SRCBTK | |
| SCHEMBL8408291 | 0.82 | TNK2 (0.39) | TNK2PKMTSHRRAF1SRC | |
| SCHEMBL10242109 | 0.82 | TNK2 (0.39) | TNK2RAF1SRCBTK | |
| SCHEMBL10242084 | 0.81 | TNK2 (0.38) | TNK2RAF1SRCBTK | |
| SCHEMBL10242104 | 0.81 | TNK2 (0.42) | TNK2RAF1SRCBTK | |
| SCHEMBL12648234 | 0.81 | TNK2 (0.42) | TNK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | TNK2 669/4885IGF1R 1033/4885KMT2A 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.